A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

June 23, 2018

Study Completion Date

June 23, 2018

Conditions

Healthy

Interventions

DRUG

Lasmiditan

Administered orally

DRUG

Placebo

Administered orally

DRUG

Diphenhydramine

Administered orally

Trial Locations (3)

Covance Clinical Research Inc, Daytona Beach

Covance Clinical Research Inc, Madison

Covance, Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT03459612 - A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants | Biotech Hunter | Biotech Hunter